Press release

Safe, fast and effective use of ZENEO® Midazolam validated by a new human factors study in the United States

Dijon, 12 September 2022

CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations, announces the successful completion of the final human factors validation study for ZENEO® Midazolam.

In June 2022, Crossject began a non-clinical validation study in the United States to assess the user's ability to inject a dose of ZENEO® Midazolam in an emergency situation under the conditions intended for the purpose. This study followed several previous studies.[1]
Sixty participants – Including 15 healthcare professionals, 15 emergency personnel, 15 adult caregivers and 15 adolescent caregivers aged 12 to 17 years – injected the product into a mannequin convulsing as if in an epileptic seizure. Only the teenagers had knowledge of the ZENEO® device prior to the test.

The results of this human factors study once again demonstrate that the ergonomics of ZENEO® are safe and effective for rapid injection in emergency situations:
- 99.6% success rate on the criteria evaluated in the use scenario;
- 43 seconds on average between the opening of the case and the injection.

This study will be used to support regulatory dossiers (Emergency Use Authorization and MA submissions).

Crossject notes that the results of the bioequivalence study[2] for ZENEO® Midazolam are expected this autumn, the injections were completed in July as planned.

[1] See press releases dated 20 March 2018 and 26 March 2020
[2] See press release dated 24 May 2022

Contacts:

Crossject
Patrick Alexandre
info@crossject.com

Investor relations
CIC Market Solutions
Catherine Couanau +33 (0)1 53 48 81 97
catherine.couanau@cic.fr

Press relations
Buzz & Compagnie
Mélanie Voisard +33 (0)3 80 43 54 89
melanie.voisard@buzzetcompagnie.com
Christelle Distinguin +33 (0)6 09 96 51 70
christelle.distinguin@buzzetcompagnie.com

About CROSSJECT • www.crossject.com

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014; it receives funding from both the BARDA (Biomedical Advanced Research and Development Authority) in the United States and Bpifrance in France.